These posts are copied from another MS board.:
Louise January 9, 2015 at 4:01 pm #
Hey Richard
Off topic, but I just saw a news release that Biogen is in phase 2 on a drug that may reverse nerve damage in optic neuritis. I know “phase 2″ and “might” but I just wanted to make sure you are aware should it be of any use to you. I kind of feel like you’re my friend now.;-)
REPLY
Grant January 11, 2015 at 6:08 am #
The drug is an Anti-LINGO monoclonal antibody (Tysabri is another well known mAb). It targets the LINGO-1 protein, which is present in certain key areas of the central nervous system and supposedly gets in the way of remyelination and regeneration of axons. The drug selectively targets the protein to interrupt its expression. Unfortunately trial results have been mixed. It’s inconclusive as yet whether the drug is effective. Like with other monoclonal antibody drugs there is also the possibility of developing PML. More should be known by the second half of 2015.
Louise January 9, 2015 at 4:01 pm #
Hey Richard
Off topic, but I just saw a news release that Biogen is in phase 2 on a drug that may reverse nerve damage in optic neuritis. I know “phase 2″ and “might” but I just wanted to make sure you are aware should it be of any use to you. I kind of feel like you’re my friend now.;-)
REPLY
Grant January 11, 2015 at 6:08 am #
The drug is an Anti-LINGO monoclonal antibody (Tysabri is another well known mAb). It targets the LINGO-1 protein, which is present in certain key areas of the central nervous system and supposedly gets in the way of remyelination and regeneration of axons. The drug selectively targets the protein to interrupt its expression. Unfortunately trial results have been mixed. It’s inconclusive as yet whether the drug is effective. Like with other monoclonal antibody drugs there is also the possibility of developing PML. More should be known by the second half of 2015.
Comment